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Summary Abnormal CA 15-3 antigen levels are found in the serum of most patients with advanced breast
carcinoma. Elevations of this marker are less frequently seen in other malignancies. Circulating CA 15-3 levels
might be useful in the differential diagnosis of the primary site of cancer. We studied the levels of CA 15-3 in
500 patients with different non-mammary cancers. Elevations of CA 15-3 (>40Urml-1) were observed in all
types of epithelial malignancies, especially in ovarian (46%), respiratory (26%) and liver (30%) carcinomas.
Abnormal values were observed in some patients with haematological malignancies and sarcomas, but not in
melanoma or neurological tumours. CA 15-3 antigen levels correlated with the extent of non-mammary
malignant tumours. Patients with locoregional cancer had a significantly smaller proportion of elevations of
the antigen than those with distant metastases (12% versus 35%, P<0.001). In particular, elevated CA 15-3
levels were observed in 70% of patients with metastatic ovarian cancer. Liver involvement by cancer did not
produce more elevations of CA 15-3 than metastases to other organs (32% versus 39%). Simultaneous
determination of circulating CA 15-3 and CA 125 antigens in 58 patients with cancer of the ovary showed
that CA 15-3 is elevated in some cases of ovarian carcinoma with non-elevated CA 125, and that CA 15-3
and CA 125 are distinct antigens. We conclude that circulating CA 15-3 antigen levels can be found elevated
in virtually all types of cancer, particularly when distant metastases are present. Therefore, CA 15-3 levels
should not be used in the differential diagnosis of the primary site in patients with metastatic malignancies
of unknown origin. Evaluation of CA 15-3 levels may enhance the sensitivity of CA 125 in monitoring the
course of ovarian carcinoma.
CA 15-3 is a cancer-associated antigen that is found in the
serum of more than 70% of patients with advanced breast
carcinoma and in a much lower proportion of patients with
non-mammary malignancies (Gion et al., 1986; Hayes et al.,
1986; Jager et al., 1986; Paulick et al., 1986; Pons-Anicet et
al., 1987). Circulating CA 15-3 antigen levels might be useful
in distinguishing breast carcinoma from other malignancies.
However, the expression of circulating CA 15-3 has not been
tested in all types of malignancies, and factors that might be
relevant to CA 15-3 levels in non-mammary cancers such as
disease extent or liver involvement have not been evaluated.
We studied the levels of the antigen CA 15-3 in a series of
500 patients with different stages of epithelial and non-
epithelial tumours, and compared the levels of CA 15-3 and
CA 125 antigens in patients with ovarian carcinoma. The
results indicate that elevated CA 15-3 antigen levels can be
observed in all types of cancer and that, in patients with
non-mammary malignancies, the levels of CA 15-3 correlate
with the presence of metastatic disease, although indepen-
dently of liver involvement. CA 15-3 antigen levels, there-
fore, should not be used in the differential diagnosis of the
primary site in advanced malignancies. The results further
show that antigen CA 15-3 is distinct from ovarian
carcinoma-associated antigen CA 125.
Patients and methods
We studied the levels of the antigen CA 15-3 in the serum of
500 patients with non-mammary cancers. Their ages ranged
from 2 to 84 years, with a mean of 58.1 + 14.6 years. Two
hundred and eight patients were female and 292 were male.
Clinical information recorded included the diagnosis of the
primary tumour and the extension of the disease, coded as
locoregional involvement, distant non-hepatic metastases and
hepatic involvement. Locoregional ovarian cancer was
divided into local and regional. In patients with ovarian
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carcinoma, we determined simultaneously the levels of the
antigen CA 125.
The series included 20 patients with primary liver cancers
(19 hepatocarcinoma and one liver sarcoma), 107 with
digestive cancers (five oesophagus, 26 stomach, 58
colorectum, seven gallbladder and 11 pancreas), 94 with
respiratory cancers (48 small cell lung cancer, 29 squamous
lung cancer, 11 lung adenocarcinoma and six others), 58
with ovarian cancer, 32 with non-ovarian gynaecological
cancers (11 uterine corpus, 15 uterine cervix and six other),
25 with urinary cancers (18 urinary bladder and seven
kidney), 22 with male genital cancers (18 prostate and four
others), 80 with haematological malignancies (22 myeloma,
21 non-Hodgkin's lymphoma, nine Hodgkin's lymphoma, 17
acute leukaemia, nine chronic leukaemia and two others),
and 62 with other malignancies (21 unknown primary
cancer, 15 head and neck, six neurologic- three gliomas,
one astrocytoma, one meningioma and one olygodendro-
glyoma with bone metastases - and 20 other, that included
six melanomas, three pediatric neuroblastomas, two
mediastinal germ cell tumours, two thymomas, one uterine
rhabdomyosarcoma, one retroperitoneal sarcoma, one syno-
viosarcoma, one liposarcoma, one osteosarcoma, one
Ewing's sarcoma and one cerebral lymphoma). Of the 420
patients with non-haematological malignancies, 269 had
locoregional disease, 56 had distant non-hepatic metastases
and 95 had liver involvement (the latter group including the
20 patients with primary liver cancer).
Serum CA 15-3 antigen was determined by sandwich
immunoradiometric assay kits supplied by International CIS
(Paris, France). Technical characteristics have been described
elsewhere (Ruibal et al., 1987). The upper limit of normality
(ULN) of circulating CA 15-3 was set at 40Uml-I as this
threshold distinguished most adequately healthy subjects and
patients with benign diseases from patients with metastatic
breast cancer (data not shown). Serum CA 125 antigen was
determined with the immunoradiometric assay supplied by
International CIS (Paris, France). The ULN of circulating
CA 125 was set at 35Uml-1.
We used x2 or Fisher's tests to study differences between
proportions, and Mann-Whitney or Kruskal-Wallis tests to
study differences between mean values. Correlations were
made using Spearman's correlation coefficients and their
significance was determined by the Student's t test.
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Results
In Table I we show the distribution of CA 15-3 levels in
patients with non-mammary cancers. We also show the
results obtained in 275 apparently healthy blood donors and
in 173 patients with metastatic breast cancer (Colomer et al.,
1988,andunpublisheddata).Thepercentageofelevatedvaluesof
CA 15-3 and the mean levels ofthe marker in the whole group
of patients with non-mammary malignancies were signifi-
cantly higher than those of the control group (P<0.01 and
P=0.001, respectively), and significantly lower than those
of patients with metastatic breast cancer (P<0.01 and
P=0.0001, respectively). Three groups of patients showed
CA 15-3 levels higher than healthy subjects: primary liver
cancer (P=0.008), respiratory cancer (P<0.0001) and ovarian
cancer (P<0.0001). Patients with locoregional cancer, distant
non-liver metastases and liver involvement all presented
CA 15-3 levels ,significantly higher than healthy subjects
(P=0.009, P<0.0001 and P<0.0001, respectively). Patients
with distant metastases had higher levels of CA 15-3 than
patients with locoregional disease (P<0.001), but no
significant differences were appreciated between patients with
or without liver involvement.
Abnormal CA 15-3 values were particularly observed in
patients with primary liver cancer (48, 50, 52, 62, 70,
70Uml-1), respiratory cancer - 9/59 with locoregional
disease (41, 49, 47, 60, 62, 64, 65, 76, 11OUml-1), 10/21
with distant non-liver metastases (42, 44, 45, 50, 61, 68, 90,
92, 110, 970Uml-1), and 6/14 with liver metastases (42, 48,
193, 200, 200, 1,200Uml-1) - and ovarian cancer - 1/8 with
local disease (47 Uml-1), 12/30 with regional disease (43, 44,
51, 70, 75, 80, 85, 90, 141, 145, 147, 162Uml-1), 4/6 with
distant non-liver metastases (42, 76, 92, 97Uml-1), and 10/
14 with liver metastases (42, 46, 48, 60, 115, 128, 1,151,
1,620, 2,000, 2,200Uml-1). The percentage of elevated
CA 15-3 was similar in patients with small cell lung cancer
(22.9%), squamous cell lung cancer (20.7%) and lung adeno-
carcinoma (36.4%). Other elevated values were observed in
3/26 patients with gastric cancer (one with lung metastases,
105 Uml-1; two with liver metastases, 200, 780Uml-1), 9/58
with colorectal cancer (six locoregional, 42, 42, 43, 47, 48,
64Uml-1; three with liver metastases, 42, 50, 290 Uml-1),
1/7 with gallbladder cancer (with liver metastases,
130Uml-1), 3/11 with pancreatic cancer (two locoregional,
41, 56Uml-1; one with liver metastases, 69Uml-1), 1/16
with endometrial carcinoma (with lung metastases,
100Uml-1), 1/6 other gynaecological cancers (one loco-
regional vulvar cancer, 44Uml-1), 2/18 with prostatic
cancer (both with bone metastases, 50, 70Uml-1), 1/22 with
myeloma (200Uml-1), 1/21 with non-Hodgkin's lymphoma
(55 Uml-1), 1/17 with acute leukaemia (200 Uml-1), 3/21
with cancer of unknown origin (one retroperitoneal nodes,
1,590Uml-P; two liver metastases, 200, 231Uml-1), 1/15
with head and neck cancer (one laryngeal carcinoma with
lung metastases, 64Uml- ), and 2/19 with other cancers
(one malignant thymoma with bone metastases, 55Uml-1;
one mediastinal teratocarcinoma with retroperitoneal
involvement, 61 Uml-1). None of the patients with
oesophageal cancer, cervix uteri cancer, urinary cancer,
Hodgkin's disease, chronic leukaemia or neurological cancer
had elevated values of CA 15-3. In addition, none of the six
patients in our series with melanoma (three of them with
liver metastases) and one of the six patients with non-hepatic
sarcomas (one uterine rhabdomyosarcoma with bone
metastases, 1,630Uml-1) had elevated CA 15-3.
CA 15-3 levels in patients with ovarian carcinoma
correlated with tumour extent (P=0.03). In this group,
elevated CA 15-3 values also occurred more frequently in
patients with more advanced cancer, although no differences
were apparent between patients with liver or non-liver
metastases, as can be seen in Table II.
CA 125 mean level in the 58 patients with ovarian
carcinoma was 516+1,004Uml-1, with a median level of
174Uml-1. Forty-nine patients (84.4%) had elevated
CA 125 values. Two of the nine patients with non-elevated
CA 125 presented abnormal levels of the antigen CA 15-3.
The combination of both markers increased the sensitivity of
CA 125 alone to 88%. In Figure 1 we show the poor
correlation between CA 15-3 and CA 125 values determined
on the same serum samples obtained from patients with
Table I Distribution of CA 15-3 values in patients with non-mammary malignancies
Group
Healthy subjects
Non-mammary cancer
Hepatic
Digestive
Respiratory
Ovarian
Gynaecological
(except ovarian)
Urinary
Male genital
Haematological
Other
Locoregional disease
Non-liver metastases
Liver involvement
No. ofpatients
No. of with CA 15-3 values
patients >40Uml-1 (%)
275
500
20
107
94
58
32
25
22
80
62
269
56
95
6 (2.2)
88 (17.6)
6 (30.0)
16 (15.0)
25 (26.6)
27 (46.6)
2 (6.2)
0
2 (9.1)
3 (3.8)
7 (11.3)
32 (11.9)
22 (39.3)
31 (32.6)
CA 15-3 levels (Uml-1)
Median Mean+s.d. (range)
15.3
17.0
22.5
15.0
24.5
35.0
15.9
14.2
12.5
11.1
14.9
17.0
25.5
23.2
16.5+9.4 (2-57)
52.5 + 198.6 (2-2,200)
30.4+21.4 (3-70)
32.0+81.6 (2-780)
57.2+ 157.7 (2-1,200)
160.5+432.5 (5-2,200)
21.0+ 12.8 (6-100)
15.2+8.7 (2-35)
17.3 + 16.6 (2-70)
18.4+30.9 (2-200)
53.8 +203.6 (2-1,630)
28.7+98.1 (1-1,590)
81.2+246.7 (3-1,630)
131.8+368.8 (2-2,200)
Metastatic breast cancer 173 130 (75.1) 90.2 283.4+457.4(7-2,500)
Table II Distribution of CA 15-3 values in patients with ovarian cancer, according to the
extension of the disease
No. ofpatients C 53lvl Ul1
No. of with CA 15-3 values (U )
Ovarian cancer patients >40Uml-1 (%) Median Mean+s.d. (range)
Local disease 8 1 (12.5) 14.0 20.0+ 14.0 (5-47)
Regional disease 30 12 (40.0) 31.0 50.6+45.6 (6-162)
Non-hepatic metastases 6 4 (66.7) 44.5 58.8 +34.4 (12-97)
Liver metastases 14 10 (71.4) 48.5 519.9 +794.4(9-2,200)CIRCULATING CA 15-3 285
Koldovsky et al., 1986; Hayes et al., 1985). This could imply
n4 - that non-mammary carcinomas do not shed 11SD8/DF3
antigen(s) to the bloodstream or rather, as will be discussed,
that circulating levels of the antigen(s) are dependent on the
presence or not of distant metastases. It is not clear why
monoclonal antibodies 115D8 and DF3, which are directed
against high molecular weight epithelial sialomucins, reacted
with the serum of patients with sarcoma or haematological
malignancies. Recently the reactivity of antibodies 115D8
and DF3 with primary non-epithelial malignancies has been
addressed (Zotter et al., unpublished data). Both 115D8 and
DF3 antibodies reacted weakly with one-third of 24
sarcomas and with some lymphomas or myelomas; DF3
antibody, but not 115D8, reacted with 3/10 brain tumours.
Neither of the two antibodies reacted with 10 melanomas,
confirming the results of Hilkens et al. (1984) with 115D8.
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CA 125 (U ml)-' sarcomas and haematological malignancies, together with the
Figure 1 Relationship between circulating CA 15-3 and CA 125 elevated circulating levels of CA 15-3 that we observed in
antigens in patients with ovarian carcinoma. Continuous lines some patients with these tumours, suggest that CA 15-3
inside the graphic indicate arbitrary upper limits of normality for detection in our study was due to a primary expression of
the respective assays. either the antigen CA 15-3 or a closely related antigen that
reacts with monoclonal antibodies 1155D8 and DF3, rather
than due to other causes like non-specific tissue damage. In
ovarian cancer. This would suggest that CA 15-3 and addition, although the antigens detected by monoclonal
CA 125 are distinct antigens that are found independently at antibodies 115D8 and DF3 are closely related (Abe et al.,
variable elevated levels in the serum of patients with ovarian 1987), the study of Zotter et al. (1989) shows unco-ordinated
carcinoma. reactivity of the antibodies within breast and other primary
tumours, suggesting that there may be intrinsic patterns of
expression of the antigens.
Discussion Our study provides the first evidence that the levels of
circulating CA 15-3 in patients with non-mammary cancer
Circulating CA 15-3 antigen levels are elevated in more than correlate with disease extent, i.e. patients with distant
70% of breast cancer patients with distant metastases (Gion metastases had significantly higher levels of CA 15-3 than
et al., 1986; Hayes et al., 1986; Jager et al., 1986; Paulick et those without. This is similar to what has been observed in
al., 1986; Pons-Anicet et al., 1986; Colomer et al., 1988). breast carcinoma. In patients with breast cancer, CA 15-3
CA 15-3 has been found useful in monitoring the course of antigen levels correlate with the presence of metastases
advanced breast cancer and in the post-surgical follow-up of (Hayes et al., 1986) and, as we have recently demonstrated,
patients with breast carcinoma (Hayes et al., 1986; Molina et with the extent of metastatic involvement (Colomer et al.,
al., 1986; Sturm et al., 1987; Yoshimoto et al., 1987; 1988). In the present study, we have shown that 70% of
Colomer et al., 1988). CA 15-3 levels might be useful in patients with metastatic ovarian carcinoma have elevated
distinguishing breast carcinoma from other types of CA 15-3 antigen levels, which is very similar to the 75% of
malignant disease. Elevated CA 15-3 antigen levels have been elevations that we observed in patients with metastatic breast
observed in selected cases of epithelial carcinomas (Gion et carcinoma (Colomer et al., 1988), and that very high values
al., 1986; Hayes et al., 1986; Jager et al., 1986; Molina et al., of CA 15-3 are observed in all types of metastatic
1986; Paulick et al., 1986). The clinical stage or liver carcinomas and also in sarcomas and haematological
involvement status of these patients, however, have not malignancies. This would suggest that CA 15-3 levels cannot
always been reported. Furthermore, patients with non- distinguish adequately between breast carcinoma and other
epithelial tumours have not been tested with the CA 15-3 neoplasms and that, therefore, CA 15-3 antigen levels should
assay. Thus, the role of CA 15-3 in the differential diagnosis not be used in the differential diagnosis of the primary site
of cancer is not established. in patients with distant metastases of uncertain origin.
We studied the levels of circulating CA 15-3 in 500 Furthermore, we have demonstrated that, in contrast with
patients with different types of non-mammary malignancies other tumour markers, hepatic involvement by non-
that included both epithelial and non-epithelial tumours, and mammary tumours does not produce higher levels of CA
evaluated the results by primary tumour type as well as by 15-3 when compared with metastatic neoplasms not affecting
disease extent and liver involvement. Our results demonstrate the liver.
that although abnormal CA 15-3 values are especially found, We compared the results of CA 15-3 with those of CA 125
as previously observed by other authors, in patients with determined in the same patients with ovarian carcinoma.
cancers of the ovary, lung and liver, elevations are observed Although the percentage of elevations of CA 125 was higher
in most types of epithelial carcinomas and, interestingly, in than that of CA 15-3 (84% versus 46%), our results suggest
some cases of lymphoma, myeloma, acute leukaemia and that the simultaneous measurement of both antigens might
uterine rhabdomyosarcoma. We observed no elevations of be clinically useful, as circulating CA 125 and CA 15-3
CA 15-3 in patients with melanoma or neurological tumours. appear to be distinct antigens and certain patients with
CA-reactive antibodies 1155D8 and DF3 detect individual normal CA 125 may have elevated levels of CA 15-3. The
antigens that are present in human primary epithelial use of both immunoassays could be beneficial in increasing
carcinomas (Hilkens et al., 1984; Kufe et al., 1984; Friedman the sensitivity in monitoring patients with ovarian
et al., 1986). Ninety-three percent of 140 human epithelial carcinoma. The antigens detected individually by monoclonal
primary tumours reacted with monoclonal antibodies 115D8 antibodies 115D8 and DF3 have been similarly found to be
or DF3, including breast, ovarian, lung and also colon and distinct from antigen CA 125 and to increase moderately the
gastric carcinomas (Zotter et al., unpublished data). The sensitivity of CA 125 in ovarian carcinoma (Koldovsky et
individual antigens detected by antibodies 115D8 and DF3, al., 1986; Sekine et al., 1985).
however, as well as CA 15-3 antigen, are detected in the In summary, the antigen CA 15-3 can be elevated in the
serum of a comparatively low percentage of patients with serum of patients with epithelial and non-epithelial non-
non-mammary epithelial tumours (Hilkens et al., 1986; mammary malignancies. In addition, CA 15-3 levels correlate
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with the presence of metastatic disease biut not with liver
involvement by tumour. Circulating CA 15-3 antigen levels
should not be used in the differential diagnosis of patients
with metastatic cancer. Finally, CA 15-3 is an antigen
distinct from CA 125 that might increase the sensitivity in
monitoring patients with ovarian carcinoma.
The authors are grateful to Drs J.M. Del Campo, D. Rubio, R.
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